Lumenis® Ltd. a global developer, manufacturer and marketer of laser, light-based and radiofrequency devices for ophthalmic, surgical and aesthetic applications, announced today that it will introduce four new ophthalmic lasers and delivery devices on November 8th at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, Georgia.
Dov Ofer, Lumenis' President and Chief Executive Officer stated: "Lumenis is proud to be yet again at the forefront of ophthalmic laser technology with the introduction of the Selecta® family of ophthalmic lasers, the Novus® Spectra(TM) Dual-Port Photocoagulator and the LumeProbe(TM) comprehensive family of premium endo photocoagulation laser probes. This industry-leading achievement stems from Lumenis' 40-year history of ophthalmic laser innovation. In 1970, we were the first company to introduce a laser in this field; since then, we have followed with a series of additional sight-preserving milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, the revolutionary Selective Laser Trabeculoplasty (SLT) system and solid state multicolor laser."
"At this year's AAO Meeting, we simply continue this long-standing tradition as we proudly showcase the newest additions to our existing and already robust product portfolio of ophthalmic lasers – a new and complete set of ophthalmic laser solutions. Our Selecta family of lasers for the ophthalmic practice offers it all – from ultimate simplicity, to comprehensive choice of therapy with maximum flexibility. Our new laser delivery devices are specifically designed to provide superior performance, as well as improve physician comfort during procedures," said Dov Ofer.
"Today, Lumenis also further expands its capabilities in the Retina segment with the introduction of the LumeProbe product family," said Gideon (Gidi) Sturlesi, Corporate Vice President & acting General Manager of Lumenis Vision, the ophthalmic business unit of Lumenis. "Our newest line of premium ophthalmic endo-photocoagulation laser probes was designed with the retina specialist in mind, featuring advanced manufacturing practices, unique fiber polishing techniques and uncompromising quality assurance methodologies that deliver product performance & reliability second to none."
"Based on over 25 years of laser probes manufacturing expertise, the LumeProbe product family was designed to deliver laser energy in the safest and most efficient manner, guaranteeing optimal clinical outcome for all relevant viteroretinal indications," concluded Mr. Sturlesi.
New Product Introduction:
Selecta® Trio(TM) – The pinnacle product in the Selecta family, the Lumenis Selecta Trio represents the next generation of multi-modality products, offering retinal, cataract and advanced glaucoma therapies in a single platform. The unit's integrated design, enhanced optics and advanced laser cavity make the Trio one of the highest performing laser products in the market – offering maximum flexibility with minimum footprint.